AbbVie Reports Head-To-Head P-III Study (SEQUENCE) of Skyrizi (risankizumab) for Crohn's Disease

Share this

AbbVie Reports Head-To-Head P-III Study (SEQUENCE) of Skyrizi (risankizumab) for Crohn's Disease


  • The P-III study evaluating risankizumab (600mg, IV at 0, 4 & 8wk. and 360mg, SC at 12wk. and q8w) vs ustekinumab (IV dose at week 0 & 90mg, SC, q8w)
  • The trial met both 1EPs of non-inferiority for clinical remission (CDAI) at 24wk. (59% vs 40%) and superiority of endoscopic remission (32% vs 16%) at 48wk. & also showed superiority for all ranked 2EPs incl. achievement of clinical remission (61% vs 41%) at 48wk., endoscopic response (45% vs 22%) at 48wk. and (45% vs 26%) at 24wk., steroid-free endoscopic remission (31% vs 15%) & clinical remission (61% vs 40%) at 48wk.
  • The safety results were consistent with the overall safety profile of risankizumab with no new safety risks. Risankizumab was approved for CD, PsA & PsO and is being evaluated for mod. to sev. UC

Ref: AbbVie | Image: AbbVie

Related News:- AbbVie’s Rinvoq (upadacitinib) Meets its Primary Endpoint in the P-IIb Study for Non-Segmental Vitiligo

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions